Docket No.

283632US0X PCT

MAR 1 4 2005 W MAR 1 4 2006 W

MAIL STOP PCT

IFW

IN THE UNITED STATES PATENT AND STADEMARK OFFICE

IN RE APPLICATION OF:

Yannick GUILLOUX, et al.

SERIAL NO:

10/561,951

GAU:

FILED:

December 22, 2005

EXAMINER:

FOR:

PEPTIDES DERIVED FROM THE PROTEIN MMP-2, AND THE USE THEREOF IN ANTITUMORAL

IMMUNOTHERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Corwin P. Umbach, Ph.D. Registration No. 40,211

Surinder Sachar

Registration No. 34,423

Customer Number


22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

MAR 1 4 2006

SHEET 1 OF 1

SERIAL NO. ATTY DOCKET NO. **Form PTO 1449** U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Modified) 10/561,951 283632US0X PCT **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Yannick GUILLOUX, et al. **GROUP** FILING DATE December 22, 2005 **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT **SUB FILING DATE CLASS** DATE NAME NUMBER INITIAL **CLASS** IF APPROPRIATE AA AB AC AD AE AF AG AH ΑI AJ AK AL **AM** AN **FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION** DATE COUNTRY NUMBER YES NO 02/098351 12/12/02 WO AO NO AP 01/80811 11/01/01 WO NO 97/45137 12/04/97 WO AQ NO AR AS AT AU ΑV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) BROOKS, Peter C. et al., "Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity", Cell, Cell Press, Vol. 92, Pages 391 - 400, 1998. AW MASSOVA, Irina et al, "Matrix metalloproteinases: structures, evolution, and diversification", FASEB Journal, Vol. 12, Pages AX 1075 - 1095, , 1998. EGEBLAD, Mikala et al., "New functions for the matrix metalloproteinases in cancer progression", Nature Reviews Cancer, AY Vol. 2, No. 3, Pages 161 - 174, 2002. ΑZ Additional References sheet(s) attached Examiner **Date Considered** *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF RELATED CASES

Examiner <u>Initial</u>	Docket No.	Serial or Patent Number	Filing or Issue Date	Patent App. <u>Publication</u> <u>No.</u>	Inventor or Applicant
	283632US0XPCT*	10/561,951	12/22/05		GUILLOUX, et al.
	258087US0XPCT	10/506,334	05/25/05		LINARD, et

Examiner

Date Considered

*Present Application; listed for information NFO/amr/hah